On December 15, the 8th China Health Industry Upgrading Summit hosted by Yiou, a well-known science and technology innovation and industrial research platform, was held in Beijing, at which the list of shortlisted companies for the CHS China Health Industry List was announced. After professional selection, Unknown Jun was awarded"2023 Top 10 Innovative Enterprises in China's Big Health Industry".Prize.
Yiou introduced that with the emergence of emerging technologies, the medical and health industry continues to break through the traditional service model and advanced methods, and carries out unprecedented changesInnovative technologies are transforming everything from diagnostics and drug discovery to disease and prevention, providing better and more efficient medical services for mankind.
In order to record innovation and evolution, Yiou Health launched the CHS China Health Industry List selection activity, and the selection is committed toSelect enterprises with vitality and innovative genes in China's big health industry and digital medical fieldTap into the core strength of the medical innovation process.
Unknown Jun participated in the selection of the "2023 China Medical and Health Industry Innovation List" with the project of "AI+FMT Personalized Intestinal Microecology Precision**". The list aims to select outstanding innovative enterprises in the fields of domestic innovation and medical devices, and selects them from the three dimensions of "technology and products", "business and market" and "economy and society".
In 2019, the US FDA proposed to focus on the development of intestinal bacteria transplantation. The microecological pharmaceutical track has successively poured into the world's top pharmaceutical companies such as Pfizer, BMS, Takeda, Merck, and Genentech, as well as cutting-edge biotechnology companies such as Unknown Jun, becoming one of the most cutting-edge and popular research fields at present.
In June 2021, Unknown Jun announced that its intestinal bacteria transplant drug codenamed "XBI-302" was approved by the US FDA for new drug clinical trials, kicking off the prelude to China's FMT microecological pharmaceutical industryThe drug is expected to enter phase II clinical studies in the near future. At the same time, Unknown Jun has also built a set of FMT production system that has been fully recognized by the US FDA.
At the same time as carrying out the drug registration application, Unknown Jun actively expands the transformation of FMT intestinal bacteria transplantation medical technology, and launches the "Personalized Intestinal Microecology Precision**" project, which will promote the AI-driven new generation of AI+FMT microbiota transplantation services to clinical application and benefit patients.
With bioinformatics analysis and metagenomic data model as the core, and intestinal bacteria transplantation as a means, the project rebuilds the intestinal microecological balance, repairs the mucosal barrier, controls inflammatory responses, enhances the body's immunity, and promotes the overall recovery of intestinal health. Autism, etc., to provide personalized and comprehensive health solutions for the intestines. On the scientific research side, Unknown Jun can jointly carry out research on FMT and indications with major hospitals.
UnknownJun's FMT solution includes a full chain of services such as supply-patient matching based on AI in-depth Xi, customized transplantation strategies, multi-dimensional effect evaluation, and precise probiotic nutrition intervention programs, bringing accurate and quantifiable clinical benefits or health improvement to patients and sub-healthy populations. The solution effectively transforms cutting-edge technologies, such as AI algorithm capabilities, disease risk capabilities, donor matching capabilities, and post-healing colonization and effect judgment, all of which have reached the industry-leading level. Unknown Jun provides a full chain of services covering pre-sale, in-sale and after-sale to reduce the medical burden and improve the efficiency of the institutionThe implementation of scientific, professional and personalized management and services has been widely praised by the industry.
In terms of product form, Unknown Jun can provide oral capsule preparations, as well as bacterial liquid preparations by enema, both of which are produced in accordance with the standards of the FDA in the United States. In terms of business, Unknown's "Personalized Intestinal Microecology Precision" project has helped big health institutions achieve new breakthroughs in medical technology, and has signed tens of millions of yuan cooperation orders with hospitals and big health institutions across the country.
The innovative technology, scheme and model of the "Personalized Intestinal Microecology Precision" project, as well as the economic and social effects with great potential, have been highly recognized by the organizing committee. Combined with the solid achievements made in drug research and development and probiotic research and development in the past year, Unknown Jun was successfully awarded the "2023 Top 10 Innovative Enterprises in China's Health Industry".
end-